Seeking Alpha

Shares of Amarin (AMRN -4.4%) spike lower after the FDA's latest Orange Book update shows no...

Shares of Amarin (AMRN -4.4%) spike lower after the FDA's latest Orange Book update shows no change in the status of its fish-oil pill Vascepa. M&A speculators had been optimistic on a decision from regulators over the exclusivity of the pill would be coming this month, because last week a draft response letter made the rounds around the FDA which made no mention of 'no decision' this month, as it has previously before.
From other sites
Comments (5)
  • alanfeuer
    , contributor
    Comments (5) | Send Message
    What's with the FDA already -- this is baloney!
    16 Nov 2012, 05:27 PM Reply Like
  • Snake Road
    , contributor
    Comment (1) | Send Message
    Novice invester. Could someone please tell me why 90% of todays volume took place after 1:15 PM ET. Optimist that I am I'd like to think that SEC rules require that a possible acquirer of amrn had to divest themselves of shares to get below a certain trigger point between tender offer and hostile takeover. wouldn't that be nice.
    17 Nov 2012, 06:12 AM Reply Like
  • chanthirani
    , contributor
    Comments (466) | Send Message
    You are too optimistic. Traders were betting on the FDA incorporating Amarin's drug Vascepa into the orange book. When that did not happen, they sold off. The sell off came after the update came out.
    17 Nov 2012, 08:24 AM Reply Like
  • gamarra
    , contributor
    Comment (1) | Send Message
    When is the next Orange Book update is going to be?
    18 Nov 2012, 06:39 AM Reply Like
  • bravo33
    , contributor
    Comments (61) | Send Message
    December 14
    19 Nov 2012, 05:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector